Police & Firemen s Retirement System of New Jersey Has $93,000 Position in AnaptysBio, Inc. $ANAB

Police & Firemen s Retirement System of New Jersey reduced its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 22.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,178 shares of the biotechnology company’s stock after selling 1,211 shares during the quarter. Police & Firemen s Retirement System of New Jersey’s holdings in AnaptysBio were worth $93,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. US Bancorp DE grew its position in shares of AnaptysBio by 126.5% in the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 979 shares during the last quarter. Brooklyn Investment Group boosted its stake in AnaptysBio by 1,779.9% in the 1st quarter. Brooklyn Investment Group now owns 6,373 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 6,034 shares during the period. Savant Capital LLC bought a new stake in AnaptysBio in the 2nd quarter valued at $241,000. Algert Global LLC acquired a new position in AnaptysBio in the 1st quarter valued at $202,000. Finally, Corton Capital Inc. increased its position in AnaptysBio by 12.2% during the 2nd quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company’s stock worth $266,000 after buying an additional 1,305 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ANAB shares. Guggenheim lifted their target price on AnaptysBio from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a research note on Wednesday, October 8th. Wells Fargo & Company increased their target price on shares of AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Wall Street Zen raised shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. Finally, Stifel Nicolaus lifted their price target on shares of AnaptysBio from $55.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $59.30.

AnaptysBio Stock Down 0.5%

Shares of AnaptysBio stock opened at $41.97 on Friday. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $43.31. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -14.88 and a beta of 0.16. The firm’s 50-day moving average price is $33.65 and its two-hundred day moving average price is $26.48.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $1.58. The company had revenue of $76.32 million during the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. On average, sell-side analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio announced that its board has authorized a stock repurchase program on Friday, November 21st that allows the company to buyback $100.00 million in shares. This buyback authorization allows the biotechnology company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its shares are undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.